These are considered to be particularly unstable and central to the disease process and to stroke generation. The current invention described the use of a phospholipid formulation that selectively blocks only antibody binding to these regions, and thus can be used to determine background for purposes of baseline determination in quantitation of unstable plaque.
Antibody-based methods have been developed to detect oxidized LDL regions of atherosclerotic plaque.